A predictor of unfavourable outcome in neutropenic paediatric patients presenting with fever of unknown origin

Pediatric Blood and Cancer

Volumn 54, Issue 2, 2010, Pages 284-290

  Semeraro, Michaela ^a   Thomée, Caroline ^b   Rolland, Estelle ^a   Le Deley, Marie Cecile ^a   Rosselini, David ^a   Troalen, Frederic ^a   Amoroso, Loredana ^a   Dubrel, Marie ^a   Hartmann, Olivier ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

Author keywords

Aplasia; Cancer; Children; FUO; Procalcitonin

Indexed keywords

ACICLOVIR; AMIKACIN; ANTINEOPLASTIC AGENT; FLUCONAZOLE; PIPERACILLIN PLUS TAZOBACTAM; PROCALCITONIN; VANCOMYCIN;

ADOLESCENT; ADULT; ANUS DISEASE; ARTICLE; BACTERIAL INFECTION; BRAIN TUMOR; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; EWING SARCOMA; FEBRILE NEUTROPENIA; FEMALE; GLIOMA; HOSPITAL ADMISSION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RECURRENT DISEASE; RETINOBLASTOMA; RISK FACTOR; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SKIN DEFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMATITIS;

ADOLESCENT; BIOLOGICAL MARKERS; CALCITONIN; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER OF UNKNOWN ORIGIN; HUMANS; INFANT; LOGISTIC MODELS; MALE; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 74849133825     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22345     Document Type: Article

References (23)

1. Fleischhack G, Cipic D, Juettner J, et al. Procalcitonin-a sensitive inflammation marker of febrile episodes in neutropenic children with cancer. Intensive Care Med 2000;26:S202-S211.
2. Slipsas NV, Bodey GP, Kontoyannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 2005;103:1103-1113.
3. Engel A, Mack E, Kern P, et al. An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients. Infection 1998;26:213-221.
4. Viscoli C, Bruzzi P, Glauser M. An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Eur J Cancer 1995;31A: 2013-2022.
5. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: Procalcitonin and IL-6 are more reliable than Creactive protein. Eur J Clin Microbiol Infect Dis 2004;23:539-544.
6. Fleischhack G, Kambeck I, Cipic D, et al. Procalcitonin in paediatric cancer patients: Its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol 2000;111:1093-1102.
7. Al-Nawas B, Shah PM. Procalcitonin, a new diagnostic and prognostic marker for severe infections. Clin Microbiol Infect 1998;4:237-241.
8. Juergens C,Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006;47:22-29.
9. Bisogno G, Ferrari A, Bergeron C, et al. The IVADo regimen - A pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: A pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group. Cancer 2005;103:1719-1724.
10. Patte C, Auperin A, Michon J, et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001;97:3370-3379.
11. Gendrel D, Bohuon C. Procalcitonin in paediatrics for differentiation of bacterial and viral infections. Intensive Care Med 2000; 26:S178-S181.
12. Maruna P, Nedelníková K, Gürlich R, et al. genetics of procalcitonin. Physiol Res 2000;49:S57-S61.
13. Tang BM, Eslick GD, Craig JC, et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: Systematic review and meta-analysis. Lancet Infect Dis 2007;7:210-217.
14. Kafkas N, Venetsanou K, Patsilinakos S, et al. Procalcitonin in acute myocardial infarction. Acute Card Care 2008;10:30-36.
15. Simon L, Saint-Louis P, Amre DK, et al. Procalcitonin and C-reactive protein as markers of bacterial infection in critically ill children at onset of systemic inflammatory response syndrome. Pediatr Crit Care Med 2008;9:407-413.
16. Gendrel D, Raymond J, Coste J, et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J 1999;18:875-881.
17. Chiesa C, Panero A, Rossi N, et al. Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. Clin Infect Dis 1998;26:664-672.
18. Ruokonen E, Nousiainen T, Pulkki K, et al. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis 1999;18:283-285.
19. Jimeno A, García-Velasco A, del Val O, et al. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumours and febrile neutropenia. Cancer 2004;100: 2462-2469.
20. Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, et al. Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 2001;32:1718-1725.
21. Santolaya ME, Alvarez AM, Aviles CL, et al. Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer, neutropenia, and fever: A prospective, multicenter trial. Pediatr Infect Dis J 2008;27:538-543.
22. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999;341:305-311.
23. Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006;24:4129-4134.